| Objective: The Yishen Huoxue Tongmai prescription is mainly based on Zuogui pill,combined with Huoxue medicine.To observe the clinical curative effect,TCM syndrome integral,DHI integral,hemorheological index,TCD index and renal function index in treating vertigo caused by vertebrobasilar insufficiency due to kidney deficiency and blood stasis.Through clinical research,in order to better evaluate the clinical efficacy and safety of Yishen Huoxue Tongmai Recipe in treating vertigo caused by deficiency of kidney and blood stasis caused by vertebrobasilar insufficiency,so as to give full play to the advantages of traditional Chinese medicine and explore a better treatment scheme.Methods: 60 patients were randomly divided into two groups,30 cases in the treatment group and 30 cases in the control group.The treatment group was given Yishen Huoxue Tongmai Recipe(200ml per bag,one dose per day,taken warm in the morning and evening),while the control group was given oral flunarizine hydrochloride capsules(2 capsules per night≤65 years old,1 capsule per night>65years old),which were treated for 4 weeks respectively.After the treatment,the changes of various indexes before and after treatment were recorded and the data were analyzed.Results:1.Comparability analysis of two groups of patients: there is no statistical difference in gender,age,course of disease,degree of illness,occupational type,basic disease composition and indicators of observation items before treatment between the two groups(P>0.05).2.Efficacy evaluation:(1)Clinical efficacy: the total effective rate of the treatment group was 93.3%,which was higher than that of the control group(80%).The results showed that both groups were effective in treating vertigo caused by deficiency of kidney and blood stasis of vertebrobasilar artery,but the total effective rate in the treatment group was higher than that in the control group,with statistical difference(P=0.015).(2)Efficacy of TCM syndrome: the total effective rate of the treatment group was90%,which was higher than that of the control group(73.3%).After examination,P=0.013,the difference was statistically significant,indicating that the clinical efficacy of Yishen Huoxue Tongmai prescription group was significantly better than that of flunarizine group.3.Evaluation of therapeutic index:(1)TCM syndrome integral: After treatment,the syndrome integral of vertigo,soreness of waist and knees,asthenia,frequent nocturnal urination,dark labial nails,forgetfulness and attack frequency of the two groups were significantly improved,with statistical significance(P<0.05).Compared with the two groups,there was no statistical difference in frequent nocturnal urination and attack frequency(P>0.05),and the other clinical syndrome treatment groups had obvious clinical effects,with statistical difference(P<0.05).Among them,the improvement of syndrome integral of physical weakness is obviously better than that of the control group,with statistical significance(P<0.01).It shows that the treatment group is better than the control group in improving the main symptoms and accompanying symptoms of vertigo due to kidney deficiency and blood stasis,such as soreness and weakness of waist and knees,fatigue,dark lips and forgetfulness.(2)Vertigo scale score: After treatment,the scores of physical symptoms,functional symptoms and emotional symptoms of the two groups were significantly improved,with statistical significance(P<0.01).After treatment,there was no significant difference in emotional symptom scores between the two groups(P>0.05),while the treatment group was significantly better than the control group in curative effect(P<0.05).(3)Hemorheological indexes: After treatment,plasma viscosity,whole blood high shear viscosity and whole blood low shear viscosity index of the two groups showed a downward trend compared with those before treatment,with statistical difference(P<0.05).There was no statistical difference between the control group and before treatment(P>0.05).After treatment,the curative effect of the treatment group was better than that of the control group in improving hemorheological indexes,and the difference was statistically significant(P<0.05).(4)TCD index: after treatment,the average blood flow velocity of vertebrobasilar artery was significantly improved in both groups(P<0.05).The vascular pulsatility index of vertebrobasilar artery in the two groups had no statistical significance except the right vertebral artery(P>0.05),and the other two indexes of left vertebral artery and basilar artery were improved compared with those before treatment(P<0.05).After treatment,the average blood flow velocity and pulse index of vertebrobasilar artery in the treatment group were better than those in the control group,and the difference was statistically significant(P<0.05).(5)Renal function index: after treatment,the urea nitrogen index of the patients in the treatment group improved both within and between groups,with statistical significance(P<0.05).There was no significant difference in the indexes of urea nitrogen in control group and serum creatinine between treatment group and control group(P>0.05).(6)Safety indicators: before and after treatment,the vital signs,laboratory tests,electrocardiogram and other indicators of the two groups were in the normal range,and no adverse reactions occurred in the two groups,indicating that both groups are safe drugs.Conclusion:(1)Yishen Huoxue Tongmai can improve the main clinical symptoms of vertigo due to vertebrobasilar insufficiency due to kidney deficiency and blood stasis,relieve the accompanying symptoms such as soreness and weakness of waist and knees,weakness and fatigue,dark lips and nails,reduce the attack frequency and improve the quality of life,which can be safely and effectively used in clinical practice.(2)Yishen Huoxue Tongmai Prescription has advantages in reducing the score of vertigo disorder scale,improving blood flow parameters of vertebrobasilar artery,reducing vascular resistance and improving plasma viscosity,thus enhancing cerebral perfusion and improving blood supply insufficiency of vertebrobasilar artery. |
PDF Full Text Request